A cocktail of Merck & Co. Inc.’s blockbuster drug Keytruda and two chemo medicines helped lung cancer patients live longer and stopped the disease from advancing.
Novartis new data reinforces superiority of Cosentyx versus Stelara in achieving skin clearance for psoriasis patients
Novartis announced results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx (secukinumab) compared to Stelara (ustekinumab) in delivering clear and almost clear skin in adults with moderate to severe plaque psoriasis at 12 weeks.
The first half of 2018 will be pivotal for Bay Area-based Rigel Pharmaceuticals Inc. as the company awaits regulatory approval for its rare blood disorder drug and builds out the internal infrastructure to commercialize the product.
Germany’s drug assessment body criticized a lack of data directly comparing drugs in a promising new class of cancer immunotherapy, saying physicians could be overwhelmed or misled by the available information.
The U.S. Food and Drug Administration approved expanded use of AstraZeneca Plc’s cancer drug Lynparza.
Forty Seven Inc. to Collaborate with Merck KGaA on Novel Immuno-Oncology Combination for Ovarian Cancer
Forty Seven Inc., a clinical-stage company focused on developing the next generation of transformational immuno-oncology treatments to enable a patient’s immune system to defeat their cancer, announced an agreement with Merck KGaA to conduct a Phase 1b clinical trial combining Hu5F9-G4 with avelumab in patients with ovarian cancer.
Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, who will have the rights to develop and commercialize therapeutic programs resulting from the collaboration.
Merck & Co. and development partner Eisai Co. snagged Breakthrough Therapy Designation from the FDA for a combo renal cell carcinoma (RCC) treatment.
Johnson & Johnson Innovation kick started 2018 by striking collaborative agreements with 15 different organizations and companies to address areas of high unmet medical need in neuroscience, oncology and other areas.
Celgene Corporation will acquire Impact Biomedicines – which is developing fedratinib for myelofibrosis and polycythemia vera – for $1.1 billion upfront.
Prescriptions for nerve pain medicines like Neurontin and Lyrica more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests.
Promacta received breakthrough therapy designation from the FDA for first-line treatment of SAA.
Novartis’ Kisqali (ribociclib) won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients.
People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.
Array BioPharma spun off some intellectual property and equipment into a new company, Yarra Therapeutics.
Odonate Therapeutics Inc. announced that it has initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer.
Novartis drug Tasigna is approved by FDA as first CML therapy with Treatment-free Remission data in its label
Novartis announced that the FDA approved the inclusion of Treatment-free Remission data in the Tasigna (nilotinib) U. S. product label.
The U.S. FDA granted priority review for Novartis’ Tafinlar in combination with Mekinist for treating some patients with advanced melanoma.
FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with Inlyta in Advanced Renal Cell Carcinoma
Merck KGaA and Pfizer Inc. announced that the U.S. FDA granted Breakthrough Therapy Designation for avelumab in combination with Inlyta (axitinib) treatment-naïve patients with advanced renal cell carcinoma.
The U.S. FDA approved Merck’s and Pfizer’s Steglatro (ertugliflozin), a sodium-glucose co-transporter 2 (SGLT2)- inhibitor, which will square off against established drugs in the market.